Project Grant R01CA292932
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$585K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
The National Cancer Institute (NCI) awarded a $1,427,270 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Syntrix Biosystems Inc. in Federal Way, WA. The grant, awarded on September 16, 2024, will fund a dose expansion study of the investigational drug SX-682, both alone and in combination with the hypomethylating agent decitabine, in patients with myelodysplastic syndromes (MDS). MDS is a pre-leukemic condition that often progresses to acute myeloid leukemia (AML), and...
This Project Grant award, valued at $148,568.00, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports research by Dr. Adrianne Wallace-Povirk, a postdoctoral fellow at the Fred Hutchinson Cancer Center, to explore the molecular mechanisms controlling CDK7 inhibitor sensitivity in pancreatic ductal adenocarcinoma (PDA). The research aims to: (1) identify how the SIRT6 tumor suppressor affects ATF4 stability,...
This Project Grant award of $1,124,896.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant aims to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. The research will be conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a National Cancer Institute-designated comprehensive cancer center in Tampa, Florida. This grant...
This Project Grant award, with a total funding amount of $237,023, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research Federal Grant Program (CFDA 93.396). The award supports the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that can jointly capture gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. The goal is to gain unprecedented insights...
The National Cancer Institute awarded a $378,674 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center (MD Anderson) to develop a small-molecule inhibitor of the EIF2AK1 protein kinase. The goal is to overcome ineffective erythropoiesis, or impaired red blood cell production, in patients with myelodysplastic syndromes (MDS) characterized by mutations in the SF3B1 gene. This novel therapeutic approach aims to address the severe anemia and...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The University of California, San Diego (UCSD) was awarded a $444,952 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to conduct research exploring the impact of base deaminase deregulation on precancer evolution. The 5-year grant, which commenced on December 1, 2024, aims to elucidate the relative roles of APOBEC3C and ADAR1 deaminases in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research...
This Project Grant award of $432,614.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, 17p loss, and NDE1 dependence in cancer cells. The goal is to define the genetic dependencies resulting from these factors and assess the therapeutic potential of targeting NDE1 in cancers with increased chromosomal instability and 17p loss. The award period...